Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
HeartSciences Inc. is a pre-revenue medical device company developing MyoVista, a non-invasive cardiac diagnostic platform designed to detect coronary artery disease and cardiac dysfunction through advanced ECG analysis. The company is in late-stage clinical development and regulatory approval phases, with no commercial sales yet generating revenue. The stock trades on clinical trial outcomes, FDA regulatory milestones, and capital raising events necessary to fund operations through commercialization.
HeartSciences is developing a proprietary cardiac diagnostic platform that aims to provide earlier, non-invasive detection of heart disease compared to traditional stress tests or imaging. The business model targets a capital equipment sale ($50K-$150K estimated per unit) followed by recurring revenue from disposables and software maintenance. Competitive advantage hinges on clinical validation demonstrating superior sensitivity/specificity versus existing modalities, potential cost savings for healthcare systems, and securing favorable reimbursement codes from CMS and private payers. Currently pre-revenue and dependent on equity financing to fund clinical trials, regulatory submissions, and initial commercialization infrastructure.
FDA regulatory milestones: 510(k) clearance or De Novo pathway approval decisions for MyoVista platform
Clinical trial data releases: Sensitivity/specificity results, peer-reviewed publications validating diagnostic accuracy
Reimbursement developments: CMS coverage decisions, CPT code assignments, private payer policy updates
Capital raising events: Equity offerings, warrant exercises, strategic partnerships that extend cash runway or signal dilution
Commercial partnerships: Distribution agreements with established medical device companies or hospital networks
Regulatory approval risk: FDA may require additional clinical data, reject application, or impose restrictive labeling that limits commercial utility and addressable market size
Reimbursement uncertainty: Failure to secure adequate CMS reimbursement rates or private payer coverage would severely limit adoption regardless of clinical efficacy
Technological obsolescence: Competing diagnostic modalities (AI-enhanced ECG, advanced imaging, biomarker panels) may offer superior performance or cost-effectiveness before MyoVista reaches market
Established competitors: Large medical device companies (GE Healthcare, Philips, Siemens Healthineers) with existing cardiology relationships, distribution networks, and bundled equipment contracts create high barriers to market entry
Alternative diagnostic pathways: Cardiologists may prefer proven modalities (stress echo, nuclear imaging, coronary CT angiography) over novel technology requiring workflow changes and staff training
Going concern risk: -$0.0B operating cash flow and -125.6% FCF yield indicate unsustainable burn rate requiring near-term capital raise to avoid liquidity crisis
Dilution risk: Equity financing at current $0.0B market cap will result in substantial shareholder dilution, particularly if raised during adverse market conditions or negative clinical news
Extreme negative margins: -201,499.5% net margin reflects pre-revenue status but highlights magnitude of capital required to reach profitability, likely requiring $50M+ in additional financing
moderate - Healthcare capital equipment purchases by hospitals are somewhat cyclical, with procurement budgets expanding during economic growth and contracting during recessions. However, diagnostic equipment addressing unmet clinical needs may receive prioritization even in downturns. Pre-revenue status insulates from immediate cyclical revenue impact but affects ability to raise capital, as risk appetite for speculative biotech/medtech declines during economic uncertainty.
Rising interest rates negatively impact HeartSciences through multiple channels: (1) higher discount rates compress valuations for pre-revenue growth companies with distant cash flows, (2) reduced risk appetite shifts capital away from speculative small-cap healthcare toward safer assets, (3) increased cost of capital for future debt financing if pursued, and (4) hospital capital budgets face pressure from higher borrowing costs for facility financing. The company's 2.42x current ratio provides near-term liquidity buffer, but sustained high rates challenge future equity raises at acceptable valuations.
Minimal direct credit exposure given pre-revenue status and limited debt (0.21x Debt/Equity). However, tightening credit conditions indirectly impact through: (1) reduced venture capital and growth equity availability for follow-on financing, (2) hospital customers facing constrained credit for capital equipment purchases post-commercialization, and (3) potential difficulties securing equipment financing partnerships for customer installations.
growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from successful FDA approval and commercialization. Typical shareholders include biotech/medtech-focused funds, retail speculators, and early-stage healthcare venture investors willing to accept binary outcomes. Not suitable for value or income investors given pre-revenue status, negative cash flows, and absence of dividends. Position sizing typically small given execution risk.
high - Pre-revenue medical device stocks exhibit extreme volatility driven by binary regulatory events, clinical data releases, and capital raising announcements. Micro-cap status ($0.0B market cap) amplifies price swings from limited liquidity and wide bid-ask spreads. Historical -20.7% six-month return reflects sector-wide derating of speculative healthcare names amid rising rates and risk-off sentiment.